FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
RALEIGH, N.C., Oct. 10, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will also host a conference call on Thursday, November 3 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 97800997. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 97800997.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, the presentation and an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
CONTACTS: Luke Heagle Pure Communications, Inc. Director, Investor Relations 910.726.1372 [email protected] or [email protected] Christine Rogers PRA Health Sciences, Inc. Director, Public Relations 919.786.8463 [email protected]
